KMDA
Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$8.54
+3.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 191.8M | 180.5M | 161.0M | 142.5M | 129.3M |
| Cost of Revenue | 113.5M | 104.1M | 91.0M | 87.0M | 82.6M |
| Gross Profit | 78.3M | 76.4M | 70.0M | 55.5M | 46.7M |
| Operating Expenses | |||||
| R&D Expense | 9.9M | 13.0M | 15.2M | 13.9M | 13.2M |
| SG&A Expense | 37.2M | 33.8M | 30.8M | 27.4M | 25.1M |
| General & Admin Expense | 26.9M | 24.1M | 20.4M | 18.3M | 15.9M |
| Selling & Marketing Expense | 10.4M | 9.7M | 10.4M | 9.2M | 9.2M |
| Other Expenses | 3.3M | 3.3M | 3.9M | 4.0M | 3.9M |
| Total Operating Expenses | 50.5M | 50.2M | 49.9M | 45.4M | 42.2M |
| Cost and Expenses | 164.0M | 154.2M | 140.9M | 132.5M | 124.8M |
| Operating Income (EBIT) | 27.8M | 26.2M | 20.1M | 10.1M | 4.5M |
| Non-Operating | |||||
| Interest Income | 1.8M | 1.9M | 2.1M | 588.0K | 91.0K |
| Interest Expense | 1.0M | 864.0K | 660.0K | 1.3M | 914.0K |
| Net Interest Income | 753.6K | 1.1M | 1.5M | (710.0K) | (823.0K) |
| Other Non-Op Income/Expense | (1.1M) | (2.8M) | (6.7M) | (1.6M) | (6.8M) |
| Non-Operating Income (excl Interest) | 1.2M | 1.9M | 6.1M | 337.0K | 5.9M |
| EBT (Pre-Tax Income) | 26.7M | 23.5M | 13.3M | 8.4M | (2.3M) |
| Income Tax Expense | 4.4M | 3.3M | (1.1M) | 145.0K | 62.0K |
| Bottom Line | |||||
| Net Income | 22.3M | 20.2M | 14.5M | 8.3M | (2.3M) |
| Earnings from Cont. Ops | 22.3M | 20.2M | 14.5M | 8.3M | (2.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 22.3M | 20.2M | 14.5M | 8.3M | (2.3M) |
| Per Share | |||||
| Basic EPS | $0.38 | $0.38 | $0.25 | $0.17 | ($0.05) |
| Diluted EPS | $0.38 | $0.37 | $0.25 | $0.15 | ($0.05) |
| Revenue Per Share | $3.31 | $3.13 | $2.80 | $2.92 | $2.89 |
| Shares | |||||
| Basic Shares Outstanding | 57.9M | 57.6M | 57.5M | 48.8M | 44.8M |
| Diluted Shares Outstanding | 57.9M | 58.3M | 57.8M | 53.7M | 44.8M |
| Profitability Metrics | |||||
| EBITDA | 42.0M | 39.2M | 27.8M | 21.2M | 10.8M |
| D&A | 15.3M | 14.9M | 13.8M | 11.5M | 12.2M |
| EBIT | 26.7M | 24.3M | 14.0M | 9.7M | (1.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026